Chemical Nameteriflunomide
Dosage FormTablets (oral; 7mg, 14mg)
Drug ClassInhibitors
CompanyGenzyme Corporation
Approval Year2012


  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aubagio (teriflunomide) Prescribing Information2012Genzyme Corporation, Cambridge, MA